Atlas Trials

Nexcella Inc.

2 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Nexcella Inc.

RecordFirmDate
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis (NCT07709715)Nexcella Inc.2027-01-01
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (NCT06097832)Nexcella Inc.2024-06-05

Track Nexcella Inc. automatically

Every clearance here is in the API, with alerts when new ones post.